KR980000443A - Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (2) - Google Patents

Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (2) Download PDF

Info

Publication number
KR980000443A
KR980000443A KR1019960020515A KR19960020515A KR980000443A KR 980000443 A KR980000443 A KR 980000443A KR 1019960020515 A KR1019960020515 A KR 1019960020515A KR 19960020515 A KR19960020515 A KR 19960020515A KR 980000443 A KR980000443 A KR 980000443A
Authority
KR
South Korea
Prior art keywords
sustained
release
pellet
terbutaline sulfate
sulfate
Prior art date
Application number
KR1019960020515A
Other languages
Korean (ko)
Other versions
KR0185291B1 (en
Inventor
김현수
민병희
최윤환
조항범
민미홍
Original Assignee
김태훈
주식회사 유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김태훈, 주식회사 유한양행 filed Critical 김태훈
Priority to KR1019960020515A priority Critical patent/KR0185291B1/en
Publication of KR980000443A publication Critical patent/KR980000443A/en
Application granted granted Critical
Publication of KR0185291B1 publication Critical patent/KR0185291B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 불황성 담체에 터부탈린설페이트(Terbrtaline sulfate), 구아이페네신(Guaifenesin) 및 겔형성제를 함유한 펠렛(Pellet)에 수불용성 피막물질이 피복된 터부탈린설페이트-구아이페네신 서방성 복합펠렛(A)과 구아이페네신 및 겔형성제를 함유한 펠렛에 수불용성 피막물질이 피복된 구아이페네신 서방성 단일펠렛(B)이 1:0.5 내지 1:3의 중량비로 혼합된 터부탈린설페이트-구아이페네신 서방성 복합제제에 관한 것이다.The present invention relates to a terbutaline sulfate-guapenesine sustained release in which a water-insoluble coating material is coated on pellets containing terbrtaline sulfate, guapenesine, and a gel-forming agent on an inert carrier. The mixed composite pellets (A) and the pellets containing the guapenesine and the gel-forming agent are mixed in a weight ratio of 1: 0.5 to 1: 3 with sustained release single pellets (B) coated with a water-insoluble coating material. The present invention relates to a terbutaline sulfate-guifenecin sustained release co-formulation.

Description

터부탈린설페이트-구아이페네신 서방성 복합제제(2)Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (2)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (8)

불황성 담체에 터부탈린설페이트(Terbrtaline sulfate), 구아이페네신(Guaifenesin) 및 겔형성제를 함유한 펠렛(Pellet)에 수불용성 피막물질이 피복된 터부탈린설페이트-구아이페네신 서방성 복합펠렛(A)과 구아이페네신 및 겔형성제를 함유한 펠렛에 수불용성 피막물질이 피복된 구아이페네신 및 겔형성제를 함유한 펠렛에 수불용성 피막물질이 피복된 구아이페네신 서방성 단일펠렛(B)이 1:0.5 내지 1:3의 중량비로 혼합된 터부탈린설페이트-구아이페네신 서방성 복합제제.Terbutaline sulfate-guipenecin sustained-release composite pellets coated with a water-insoluble coating material on pellets containing terbrtaline sulfate, guapenesine, and gel-forming agents on inert carriers (A) and guipenesine sustained release coated with a water-insoluble coating material in a pellet containing a water-insoluble coating material in a pellet containing a guapenesine and a gel-forming agent Terbutaline sulfate-guifenecin sustained release composite preparation in which a single pellet (B) is mixed in a weight ratio of 1: 0.5 to 1: 3. 제1항에 있어서, 상기 서방성 복합펠렛(A) 및 상기 서방성 단일펠렛(B)에 함유되는 구아이페네신의 중량비가 1:0.5 내지 1:3임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.The method of claim 1, wherein the weight ratio of guipenesin contained in the sustained-release composite pellet (A) and the sustained-release single pellet (B) is 1: 0.5 to 1: 3 terbutaline sulfate-Guiape Necine sustained release combination. 제1항에 있어서, 상기 서방성 복합펠렛(A) 및상기 서방성 단일펠렛(B)에 함유되는 겔형성제가 미결정셀룰로오스, 히드록시프로필셀룰로오스, 히드록시프로필메칠셀룰로오스, 폴리비닐피롤리돈 또는 이들의 혼합물중에서 선택된 것임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.The method of claim 1, wherein the gel-forming agent contained in the sustained-release composite pellet (A) and the sustained-release single pellet (B) is microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone or these Terbutalin sulfate-guifenecin sustained release combinations, characterized in that selected from the mixture of. 제3항에 있어서, 상기 겔형성제가 서방성 복합펠렛(A) 또는 서방성 단일 펠렛(B)의 총중량에 대하여 5~50중량%임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.According to claim 3, wherein the gel-forming agent terbutaline sulfate-guipenesine sustained-release composite preparation, characterized in that 5 to 50% by weight relative to the total weight of the sustained-release composite pellet (A) or a sustained release single pellet (B). . 제1항에 있어서, 상기 서방성 복합펠렛(A) 및 상기 서방성 단일펠렛(B)에 함유되는 수불용성 피막물질이 에칠셀룰로오스, 히드로제네이티드카스터오일, 슈어릴리즈(Surelease, Colorcon사), 유드라짇 또는 이들의 혼합물중에서 선택된 것임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.The method of claim 1, wherein the water-insoluble coating material contained in the sustained-release composite pellet (A) and the sustained-release single pellet (B) is ethyl cellulose, hydrogenated castor oil, Surelease (Surelease) , Colorcon), Eudrapon or mixtures thereof. 제5항에 있어서, 상기 수불용성 피막물질이 서방성 복합펠렛(A) 또는 서방성 단일펠렛(B)의 총중량에 대하여 1~20중량%임을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합제제.The method of claim 5, wherein the water-insoluble coating material is 1 to 20% by weight relative to the total weight of the sustained-release composite pellet (A) or a sustained-release single pellet (B) terbutaline sulfate-guapenesine sustained release Combinations. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 터부탈린설페이트-구아이페네신 서방성 복합제제를 경질캅셀에 충전한 것을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합칼셀제.7. The terbutaline sulfate-guifenesine sustained-release complexed calcined agent according to any one of claims 1 to 6, wherein a hard capsule is filled with the terbutaline sulfate-guifenesine sustained release complex preparation. . 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 터부탈린설페이트-구아이페네신 서방성 복합제제를 타정한 것을 특징으로 하는 터부탈린설페이트-구아이페네신 서방성 복합정제(Spacetab).The terbutaline sulfate-guiphenesine sustained-release complex tablet according to any one of claims 1 to 6, wherein the terbutaline sulfate-guiphenesin sustained release complex preparation is compressed. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960020515A 1996-06-10 1996-06-10 Extended release composition containing terbutaline sulfate and guaifenesin(2) KR0185291B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019960020515A KR0185291B1 (en) 1996-06-10 1996-06-10 Extended release composition containing terbutaline sulfate and guaifenesin(2)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019960020515A KR0185291B1 (en) 1996-06-10 1996-06-10 Extended release composition containing terbutaline sulfate and guaifenesin(2)

Publications (2)

Publication Number Publication Date
KR980000443A true KR980000443A (en) 1998-03-30
KR0185291B1 KR0185291B1 (en) 1999-05-01

Family

ID=19461230

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960020515A KR0185291B1 (en) 1996-06-10 1996-06-10 Extended release composition containing terbutaline sulfate and guaifenesin(2)

Country Status (1)

Country Link
KR (1) KR0185291B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024005758A1 (en) * 2022-06-29 2024-01-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A stable oral liquid composition comprising terbutaline & guaifenesin

Also Published As

Publication number Publication date
KR0185291B1 (en) 1999-05-01

Similar Documents

Publication Publication Date Title
KR880001289A (en) Sustained release formulations and preparation methods thereof
KR930003905A (en) Pharmaceutical binding agents
DE59409568D1 (en) ACTIVE SUBSTANCES AND GAS CONTAINING MICROPARTICLES
KR890009380A (en) Sustained-release pharmaceuticals
KR840005016A (en) Method for preparing sustained release tablet
NZ515230A (en) Fast-dispersing dosage forms containing fish gelatin
KR900015734A (en) Osmotic continuous release oral delivery system containing a pharmaceutically acceptable active ingredient with improved core membrane adsorption properties
BG106398A (en) Method for making granules with masked taste and instant release of the active particle
DK0868912T3 (en) Use of redispersible polymer powders or polymer granules for coating pharmaceutical or agrochemical application forms
CA2016039A1 (en) Extended release pharmaceutical formulations
CA2211284A1 (en) Multiple unit sustained release dosage form
MX9701465A (en) Acetaminophen sustained-release formulation.
TW340045B (en) Extended zero order release pharmaceutical composition
GB8603523D0 (en) Slow release formulation
TR199901147T2 (en) Grains that disperse quickly.
KR970703133A (en) Process for Producing Active Agent Preparations in the Form of a Solid Solution of the Active Agent in a Polymer Matrix and Active Agent Preparations Obtained Thereby
KR870003780A (en) Multi-Granules
DK0868910T3 (en) Use of Redispersible Polymer Powders or Polymer Granules as Binders for Preparation of Solid Pharmaceutical Dispersing Forms
HUP9903869A2 (en) Oral composition comprising a triazole antifungal compound
KR880000090A (en) Method for preparing sustained release ibuprofen formulation
ATE370980T1 (en) SPHERICAL POWDER COMPONENTS AND SOLID COSMETIC COMPOSITION CONTAINING SAME
HUP9900365A3 (en) N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
KR980000443A (en) Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (2)
KR980000442A (en) Terbutalin Sulfate-Guifenecin Sustained Release Combination Preparation (1)
DK1105099T3 (en) Composition of fish gelatin for use as an ingredient in tablets

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030204

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee